๐น EPS: $0.45 (Est. $0.50) ๐ด
๐น Revenue: $1.114B (Est. $1.103B) ๐ข; UP +8% YoY
2025 Guidance:
๐น Revenue: $4.60B (14% growth)
๐น Non-GAAP Gross Profit Margin: ~64%-65%
๐น Non-GAAP Operating Margin: ~21%
๐น Adjusted EBITDA Margin: ~30%
Q4'24 Segment & Geographical Performance:
๐น U.S. Revenue: $796.2M (UP +4% YoY) ๐ก
๐น International Revenue: $317.8M (UP +17% YoY) ๐ข
Key Metrics:
๐น Non-GAAP Gross Profit: $661.2M (59.4% margin; Est. 62.34%) ๐ด
๐น Non-GAAP Operating Income: $209.5M (18.8% margin)
๐น GAAP Net Income: $151.7M; Non-GAAP Net Income: $177.8M
๐น Cash & Liquidity: $2.58B in cash and equivalents
Strategic and Business Updates:
๐ธ Submitted Dexcom G7 15-day CGM system to FDA for review
๐ธ Secured reimbursement for Dexcom ONE+ in France, expanding access to CGM for Type 2 diabetes patients
๐ธ Announced partnership with ลURA to integrate glucose data with activity, sleep, and stress metrics
๐ธ Launched generative AI-powered features to provide personalized glucose insights
Management Commentary:
๐ธ Kevin Sayer, Chairman and CEO:
โIn 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo, and submitted our G7 15-day product to the FDA. As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.โ